A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer is a research paper published in Clinical Genitourinary Cancer (2020). On theSindex it has a DataRank of 0.425. It has been cited 16 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.425
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: P30 CA016672
NIGMS NIH HHS
Grant: U54 GM104942
Pfizer
AstraZeneca
Genentech
Sanofi
Janssen Pharmaceuticals
Merck
Astellas Pharma US
Bayer Fund
National Institutes of Health
Prostate Cancer Foundation
Bristol-Myers Squibb
Exelixis
FWCI
0.99
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals